| Trial ID: | L6461 |
| Source ID: | NCT01147861
|
| Associated Drug: |
Gsk256073
|
| Title: |
A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: GSK256073|DRUG: GSK256073|DRUG: GSK256073|DRUG: GSK256073|OTHER: Placebo
|
| Outcome Measures: |
Primary: Weighted mean AUC for glucose, 24 hours | Secondary: Weighted mean AUC for NEFA, glycerol, triglycerides, insulin, and C-peptide, 24 hours
|
| Sponsor/Collaborators: |
Sponsor: GlaxoSmithKline
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
39
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT
|
| Start Date: |
2010-07-01
|
| Completion Date: |
2010-09-07
|
| Results First Posted: |
|
| Last Update Posted: |
2017-06-14
|
| Locations: |
GSK Investigational Site, Anniston, Alabama, 36207, United States|GSK Investigational Site, Miami Gardens, Florida, 33169, United States|GSK Investigational Site, Miami, Florida, 33169, United States|GSK Investigational Site, San Antonio, Texas, 78229, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01147861
|
